We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

By LabMedica International staff writers
Posted on 04 Oct 2015
Print article
The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company.

Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI) at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) have agreed to accelerate the discovery of fully human antibodies directed against therapeutic targets being studied by investigators at Mount Sinai.

Regeneron will provide Mount Sinai with access to its proprietary VelocImmune technology and will provide financial support to use this antibody discovery platform to generate antibodies against targets of interest and explore potential therapeutic applications for human disease.

Fully-human monoclonal antibodies are highly desirable as therapeutic agents, for in addition to the advantages of being very specific for and tightly binding to their therapeutic targets, fully-human antibodies avoid potential immune responses that may occur in patients receiving antibodies that contain nonhuman (typically mouse) components.

The Regeneron VelocImmune mouse uniquely expresses human antibody genes in the same robust fashion that mouse genes are typically expressed. Previously engineered human monoclonal antibody-producing mice were generated with old technologies that resulted in removal of the mouse constant regions that are critical for the mouse to make a strong immune response. In contrast, VelocImmune mice preserve the mouse constant regions and, therefore, have immune systems that mount a robust, humoral-immune response that is indistinguishable from that of a normal, wild-type mouse.

Mount Sinai has agreed to undertake preclinical research operations, and Regeneron has been granted an exclusive option to negotiate a license for future clinical development and commercialization of any antibody that is developed.

"It is through partnerships like this that Mount Sinai remains on the forefront of translational research and therapeutic discoveries, and we hope to soon see the fruits of our collaboration with Regeneron," said Dr. Dennis S. Charney, dean of the Icahn School of Medicine at Mount Sinai.

"This agreement brings together Mount Sinai's deep biology and clinical expertise and Regeneron's unique antibody technology," said Dr. Drew Murphy, senior vice president for research at Regeneron. "Both our organizations are part of the rapidly maturing New York bioscience ecosystem and share a deep commitment to improving human health by pursuing innovative science."

Related Links:

Regeneron Pharmaceuticals, Inc. 
Icahn School of Medicine at Mount Sinai


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.